BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 19 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 21 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 21 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 19 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 21 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 21 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
AlphaGraphs

ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report

Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an increase in revenue. The company also raised its full-year earnings guidance. Net revenues increased to $15.8 billion in the September quarter from $14.5 billion in the corresponding period of fiscal 2024. Net earnings, […]

October 31, 2025 1 min read

Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an increase in revenue. The company also raised its full-year earnings guidance. Net revenues increased to $15.8 billion in the September quarter from $14.5 billion in the corresponding period of fiscal 2024. Net earnings, […]

· October 31, 2025

Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an increase in revenue. The company also raised its full-year earnings guidance.

AbbVie, Inc. Q3 2025 Earnings

Net revenues increased to $15.8 billion in the September quarter from $14.5 billion in the corresponding period of fiscal 2024.

Net earnings, on an adjusted basis, declined to $1.86 per share in the third quarter from $3.0 per share in the year-ago quarter. Net income attributable to the company, on a reported basis, was $186 million or $0.10 per share in Q3, compared to $1.56 billion or $0.88 per share last year.

The management raised its full-year 2025 adjusted earnings guidance range from $10.38-0.58 per share to $10.61-$10.65 per share. The revised guidance includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter.

ADVERTISEMENT
ADVERTISEMENT